Summary
Alteration in interactions between tumor-infiltrating lymphocytes (TILs) and tumor cells after chemotherapy or immunotherapy was studied in metastatic melanoma patients. Tumors were harvested from surgical specimens 17 days after the end of chemotherapy with cisplatin, vinblastine, and dacarbazine (CVD). Tumors of nonlymph-node metastases from two responders yielded neither TILs nor tumor cells, whereas those from all four nonresponders had both TILs [(1.1−13.8) × 106 cells/g tumor] and tumor cells [(2.8−30.8) × 106 cells/g tumor). Tumors of lymph node metastases from nine patients yielded substantial numbers both of TILs and tumor cells, regardless of different clinical responses, except with one complete responder, whose tumor did not contain tumor cells. The mean increase of TILs from these tumors (n = 14) 3–4 weeks after incubation with 200 U/ml recombinant interleukin-2 (rIL-2) was 2.5-fold, whereas there was a 56-fold increase in TILs from untreated tumors (n = 3). CD3+ T cells predominated in TILs before and after expansion with IL-2. IL-2-activated TILs from five of six tumors tested displayed higher cytotoxicity against autologous tumor cells than against cells from any of three allogeneic tumors. Mean tumor cell numbers (106 cells/trial) obtained by serial needle biopsies for the same tumor in five patients decreased from 1.2 before therapy to 0.25 at day 4 of therapy (interferon α alone), and to 0.02 at day 8 (interferon α and IL-2). This decrease did not correlate with clinical responses. Yields (× 106 cells/g tumor) of TILs and tumor cells in subcutaneous melanomas obtained by excisional biopsies in one nonresponder under IL-2 therapy were respectively 0.2 and 1.1 before therapy (day 0), 0.1 and <0.01 during (day 7), 0.2 and <0.01 at the end of therapy (day 21), and 0.5 and 0.5 at the time of tumor progression (day 66). Yields of TILs and tumor cells in the other nonresponder were respectively 3 and 26 before (day 0), 16 and 3 during (day 7), and 0.4 and <0.01 at the end of IL-2 therapy (day 17), and 2.5 and 6 at the time of progression (day 62). TILs in these two patients before therapy proliferated well in culture with IL-2 (570-and 720-fold, respectively), and showed higher cytotoxicity against autologous tumor cells, whereas none of those from the five tumors biopsied during or at the end of IL-2 therapy proliferated. TILs at the time of progression showed modest proliferation (54- and 76-fold, respectively) and showed major-histocompatibility-complexnonrestricted cytotoxicity. In summary, a decrease in the number of live tumor cells did not always correlate with clinical response in either therapy. CVD chemotherapy may simply impair IL-2-induced proliferation of TILs. IL-2 therapy may induce transient unresponsiveness of TILs to IL-2.
Similar content being viewed by others
References
Balch CM, Riley LB, Bae Y-J, Salmeron MA, Platsoucas CD, von Eschenbach Ac, Itoh K (1990) Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 126: 200–205
Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell carcinoma: isolation, characterization, and anti-tumor immunity. Cancer Res 48: 206–214
Belldegrun A, Kasid A, Uppenkamp M, Topalian SL and Rosenberg SA (1989) Human tumor-infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 142: 4520–4526
Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Pietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA, Hawkins MJ, Atkins MB, Ciobanua N, Ellis TM (1988) Laboratory correlates of adoptive immunotherapy with recombinant interleukin 2 and lymphokine-activated killer cells in humans. Cancer Res 48: 4409–4416
Cameron RB, McIntosh JK, Rosenberg SA (1988) Synergistic antitumor effects of combination immunotherapy with recombinant interleukin 2 (IL2) and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 48: 5810–5817
Cortesina G, DeStefani A, Giovarelli M, Baroglio MG, Cavallo G, Jemma C, Forni G (1988) Treatment of recurrent squamous cell carcinoma of head and neck with low doses of interleukin 2 (IL2) injected perilymphatically. Cancer 62: 2482–2487
Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA (1989) Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7: 250–261
Foon KA (1989) Biological response modifiers: the new immunotherapy. Cancer Res 49: 1621–1639
Heo DS, Whiteside TL, Johnson JT, Chen KN, Barnes EL, Herberman RB (1987) Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res 47: 6353–6362
Hirsh M, Lipton A, Harvey H, Givant E, Hopper K, Jones G, Zeffren J, Levitt D (1990) Phase I study of interleukin 2 and interferon alpha-2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol 8: 1657–1663
Itoh K, Tilden AB, Balch CM (1986) Interleukin 2 activation of cytotoxic T lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46: 3011–3017
Itoh K, Platsoucas CD, Balch CM (1988) Autologous specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 or autologous tumor cells, and involvement of the T cell receptor. J Exp Med 168: 1419–1441
Kupper MC, Hamou MF, de Tribolet N (1988) Immunohistological and functional analysis of lymphoid infiltrates in human glioblastomas. Cancer Res 48: 6926–6932
Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA (1986) Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 38: 367–380
Lafreniere R, Borkenhagen K, Bryant LD, Ng E (1989) Tumor-infiltratinglymphocytes cultured in recombinant interleukin 2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvest. J Biol Response Mod 8: 238–251
Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer MC, Rosenberg SA (1985) In vivo administration of purified human interleukin 2: II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 135: 2865–2875
Mansfield PF, Salmeron MA, Itoh K, Murray JL, Rosenblum MG (1989) Activation of human melanoma tumor-infiltrating lymphocytes (TIL) by a heteroconjugate of anti CD3-anti p97 monoclonal antibodies followed by interleukin 2. Proc Am Assoc Cancer Res 30: 402
Muul LM, Spiess PJ, Director EP, Rosenberg SA (1987) Identification of specific cytotoxic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138: 989–995
Nakamura H, Ishiguro K, Mori T (1988) Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Cancer 62: 2489–2497
Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A (1987) Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 47: 173–177
Rabinowich H, Stiner Z, Klajman A (1987) Clonal analysis of human tumor infiltrating lymphocytes reactive with autologous tumor cells: different target cell specifications of NK-like and cytotoxic T cell clones. Cell Immunol 104: 210–217
Rivoltini L, Gambacorti-Passerini C, Squadrelli-Saraceno M, Grosso MI, Cantu G, Molinari R, Orazi A, Parmiani G (1990) In vivo interleukin 2-induce activation of lymphokine-activated killer cells and tumor cytotoxic T cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res 50: 5551–5557
Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 223: 1318–1321
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian S, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei J, White DE (1988) Use of TIL and IL-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676–1688
Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT (1989) Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 49: 7086–7092
Takagi S, Chen K, Schwarz R, Iwatsuki S, Herberman RB, Whiteside TL (1989) Functional and phenotypic analysis of tumorinfiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer 63: 102–111
Tilden AB, Itoh K and Balch CM (1987) Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. J Immunol 138: 1068–1073
Tsujihashi H, Matsuda H, Uejuma S, Akiyama T, Kurita T (1988) Immunocompetence of tissue infiltrating lymphocytes in bladder tumors. J Urol 140: 890–894
Author information
Authors and Affiliations
Additional information
This work was supported in part by grant CA 47 891 from the National Institutes of Health and a grant from the University Cancer Foundation, and Mr Richard Hunton Melanoma Found.
Rights and permissions
About this article
Cite this article
Itoh, K., Hayakawa, K., Salmeron, M.A. et al. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. Cancer Immunol Immunother 33, 238–246 (1991). https://doi.org/10.1007/BF01744943
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01744943